RT Journal Article
SR Electronic
T1 Lifespan analysis of repeat expression reveals age-dependent upregulation of HERV-K in the neurotypical human brain
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.17.24307184
DO 10.1101/2024.05.17.24307184
A1 Evans, Taylor A.
A1 Feltrin, Arthur S.
A1 Benjamin, Kynon J.
A1 Katipalli, Tarun
A1 Hyde, Thomas
A1 Kleinman, Joel E.
A1 Weinberger, Daniel R.
A1 Paquola, Apua C.
A1 Erwin, Jennifer A.
YR 2024
UL http://medrxiv.org/content/early/2024/05/17/2024.05.17.24307184.abstract
AB DNA repetitive sequences (or repeats) comprise over 50% of the human genome and have a crucial regulatory role, specifically regulating transcription machinery. The human brain is the tissue with the highest detectable repeat expression and dysregulations on the repeat activity are related to several neurological and neurodegenerative disorders, as repeat-derived products can stimulate a pro-inflammatory response. Even so, it is unclear how repeat expression acts on the aging neurotypical brain. Here, we leverage a large postmortem transcriptome cohort spanning the human lifespan to assess global repeat expression in the neurotypical brain. We identified 21,696 differentially expressed repeats (DERs) that varied across seven age bins (Prenatal; 0-15; 16-29; 30-39; 40-49; 50-59; 60+) across the caudate nucleus (n=271), dorsolateral prefrontal cortex (n=304), and hippocampus (n=310). Interestingly, we found that long interspersed nuclear elements and long terminal repeats (LTRs) DERs were the most abundant repeat families when comparing infants to early adolescence (0-15) with older adults (60+). Of these differentially regulated LTRs, we identified 17 shared across all brain regions, including increased expression of HERV-K-int in older adult brains (60+). Co-expression analysis from each of the three brain regions also showed repeats from the HERV subfamily were intramodular hubs in its subnetworks. While we do not observe a strong global relationship between repeat expression and age, we identified HERV-K as a repeat signature associated with the aging neurotypical brain. Our study is the first global assessment of repeat expression in the neurotypical brain.Competing Interest StatementD.R.W. serves on the Scientific Advisory Boards of Sage Therapeutics and Pasithea Therapeutics. J.E.K. has served as a consultant for Merck on an antipsychotic drug trial. All other authors declare no competing interests.Funding StatementThis work is supported by the Lieber Institute for Brain Development. JAE is supported by a NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation and Collaborative Center For X-Linked Dystonia Parkinsonism and the MGH Collaborative Center for X-Linked Dystonia-Parkinsonism. JAE and ASF are supported by the Maryland Stem Cell Research Foundation. KJB is supported by T32 fellowship (T32MH015330) and K99 award (K99MD016964).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used openly available human data (upon researcher registration) located at Globus (https://research.libd.org/globus/) and dbGaP (https://www.ncbi.nlm.nih.gov/gap/)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes